Use Cases | Japan Oncology RWD Portal

EMR RWD

Clinical feasibility, treatment landscape, and biomarker availability

Cyber Oncology answers questions that start from routine clinical care: tumor type, stage, biomarker testing, line of therapy, medication exposure, labs, response, and safety.

Indication & Market Understanding

Treatment landscape, line-of-therapy sequencing, biomarker testing rates, addressable populations, and Japan-specific standard of care.

Trial Design & Feasibility

Patient counts against inclusion/exclusion criteria, endpoint availability, and site concentration for feasible enrollment planning.

Post-Approval & Label Expansion

Real-world outcomes by therapy line, CTCAE-graded safety, HEOR endpoints, and subpopulation evidence.

Biomarker test results by tumor type

Approximate screened patients per biomarker, sourced from NTT catalog (Dec. 2025). This table was moved from Data Catalog to keep analysis examples together.

Biomarker	BC	NSCLC	CRC	PDAC	GC	HCC	EC	OC	SCLC	BTC
ER	3,880	-	-	-	-	-	-	260	-	-
PR	3,760	-	-	-	-	-	-	140	-	-
HER2	5,480	-	<100	-	800	-	-	-	-	-
Ki-67	2,160	<100	-	-	-	-	-	-	<100	-
EGFR	<100	1,360	<100	-	-	-	-	-	<100	-
ALK fusion	-	1,060	-	-	-	-	-	-	<100	-
PD-L1	<100	1,260	-	-	<100	-	<100	<100	<100	-
ROS1 fusion	-	750	-	-	-	-	-	-	-	-
BRAF	-	610	440	-	-	-	-	-	-	-
KRAS	-	<100	500	-	-	-	-	-	-	-
MSI	<100	-	160	<100	110	<100	<100	<100	-	<100
MIB-1	1,670	-	<100	-	<100	-	<100	<100	<100	-

Biomarkers have been obtained for approximately half of the cases in the patient totals. Expansion is ongoing.

NSCLC - Osimertinib 1L (EGFR+)

11 sites - 2018-2022 - Mar. 2026 estimate

Cohort filter	Patients
Total NSCLC	4,497
Advanced/metastatic (IIIb-IV)	2,719
Tested for EGFR	1,391
EGFR(+)	407
Common EGFR	281
EGFR TKI received	279
Osimertinib as 1L	246
Osimertinib 1L monotherapy after Apr. 2018	246

BC - CDK4/6 inhibitor (HR+/HER2-)

11 sites - 2018-2023 - Mar. 2026 estimate

Cohort filter	Patients
Total BC	10,247
Advanced/metastatic (IIIb-IV)	1,247
Tested for HR	736
HR(+)	558
Tested for HER2	880
HER2(-)	672
HR(+) & HER2(-)	413
CDK4/6 inhibitor after HR/HER2 test	222

Breast cancer - stage x biomarker testing matrix

Mar. 2026 estimate only. Positive biomarker counts require follow-up discussion because additional collection incurs cost.

Stage	Patients	ER tested	PR tested	HER2 tested	Ki-67 tested
Stage I	4,776	2,887	2,815	3,484	1,738
Stage II	3,860	2,312	2,290	2,806	1,379
Stage III	944	559	548	702	389
Stage IV	665	347	343	470	233

Prostate cancer - 15-facility projected matrix

15-facility projected matrix. Includes patients who underwent surgery or radiation therapy. Medication estimates are calculated from the 7-facility subset and projected to the 15-facility network.

Stage	Patients	Anti-androgens				Taxane	BMA	Pluvicto
Stage	Patients	Any	Gen 1	Gen 2	CYP17 inh.	Taxane	BMA	Pluvicto
ALL	15,730	12,220	10,940	2,570	1,230	1,050	1,750	0
Stage 0	0	0	0	0	0	0	0	0
Stage I	5,090	3,510	3,450	120	60	60	60	0
Stage II	3,280	2,340	2,340	120	60	60	60	0
Stage III	2,750	2,220	2,160	290	60	120	60	0
Stage IV	4,330	3,920	2,750	2,050	1,110	760	1,520	0
Other	350	290	290	60	0	0	0	0

Sankey chart showing prostate cancer treatment history across lines of therapy — **Prostate cancer patient treatment-history analysis** Visualizes therapy sequence transitions across 1L to 5L, including ARPI, taxane, and other treatment pathways.

Time to next treatment curve for first-line prostate cancer therapy — **Time to Next Treatment analysis** Shows time from current-line start to next-line therapy, with ongoing patients treated as censored observations.

CLINICO-GENOMICS

Mutation-defined cohorts, outcomes, and translational evidence

VAPORCONE supports condition setting across enrollment, specimen, event, treatment, genome, and biomarker fields, then lets teams move from aggregate search into study-level and patient-level review.

Research topic overview

23,096

Selecting a research topic displays a topic overview and total data context before filters are applied.

Search modules

Basic InfoEnroll InfoSpecimen InfoEvent InfoTreatment InfoGenome InfoSpecific Biomarker Info

Endpoint readiness

OS PFS

Use OS/PFS as analysis targets after confirming survival, response, RECIST, ECOG PS, and assessment-date availability per cohort.

Search condition modules available in VAPORCONE

These modules remain the main way to define cohorts before moving into VAPORCONE's screen-based review, file access, and analytics views.

Module	Representative filters	Use case
Basic Info	Cancer type, main occupation, core patient attributes	Define the starting population and indication scope.
Enroll Info	Study enrollment attributes and study participation	Size the available cohort before applying genomic or outcome filters.
Specimen Info	Visit, sample type, assay method, test target	Confirm tissue, blood, ctDNA, MRD, MSI, or TMB evidence availability.
Event Info	Alive/dead, drug name, discontinuation reason, CR/PR/SD/PD/NE, MSI-H/L/MSS, TMB-H/L	Link molecular cohorts to exposure, response, progression, and survival-related status.
Treatment Info	Reason for discontinuation, surgery location, concomitant drugs, chemotherapy drug name, best overall response	Evaluate treatment sequences and response-defined subgroups.
Genome Info	Gene symbol, CNV, short variation, sequence rearrangement, SNV, transcription	Find alteration-defined cohorts across SNV, CNV, fusion, and transcript-level filters.
Specific Biomarker Info	Visit, test target, sample type, assay method, manual input fields	Handle targeted questions such as MSI status, MRD timing, and named biomarker tests.

VAPORCONE portal entry screen for RWE analytics and study office workflows — **Medical Innovation Cyber Space** VAPORCONE acts as an integrated SCRUM-Japan data workspace where users enter RWE analytics and study-office workflows from a single portal.

VAPORCONE study list showing accession numbers, studies, and participant counts — **Cross-study cohort discovery** Users can inspect SCRUM-Japan studies stored in VAPORCONE and identify target cohort sources by study category, accession number, and participant volume.

VAPORCONE patient treatment-history table with medication sequence and treatment dates — **Treatment-history review** Patient-level treatment history can be reviewed by medication sequence, treatment epoch, start and end dates, and drug category.

VAPORCONE genetic data raw file list with BAM FastQ VCF and report files — **Genomic raw-file access** Genomic source and analysis files such as BAM, FastQ, VCF, XML, TSV, and reports can be listed for downstream review where available.

VAPORCONE image data list showing diagnostic reports and pathology image files — **Image data inventory** Users can confirm image-data availability, including diagnostic reports and pathology image files such as HE, HER2, IHC, and PDL1 stains.

VAPORCONE disease response and subject status tables for outcome review — **Outcome and response review** Outcome tables show response, progression, ECOG PS, RECIST-linked assessment, survival status, and assessment dates for patient-level review.

VAPORCONE charts and graphs dashboard with distributions mutation chart OS and PFS panels — **Built-in charts and graph tools** VAPORCONE provides dashboard-style charting for cohort understanding, including age, cancer type, stage, gender, mutation, OS, and PFS views.

VAPORCONE progression-free survival comparison chart for selected patient groups — **PFS comparison between selected cohorts** Selected patient groups can be compared using progression-free survival curves, supporting biomarker or subgroup-level outcome exploration.

Patient and study review

Study-level cohort source and participant review
Patient-level treatment history and medication sequence
Clinical, genomic, image, and outcome data availability checks

Endpoint review

Response, progression, survival status, and assessment dates
OS and PFS dashboard views for selected cohorts
PFS comparison between biomarker-defined groups

Evidence package

Raw genomic files and structured clinical tables
Pathology and diagnostic image inventory
Analytics views for cohort understanding and research scoping

Use Cases by Data Asset

Clinical feasibility, treatment landscape, and biomarker availability

Indication & Market Understanding

Trial Design & Feasibility

Post-Approval & Label Expansion

Biomarker test results by tumor type

NSCLC - Osimertinib 1L (EGFR+)

BC - CDK4/6 inhibitor (HR+/HER2-)

Breast cancer - stage x biomarker testing matrix

Prostate cancer - 15-facility projected matrix

Mutation-defined cohorts, outcomes, and translational evidence

Research topic overview

Search modules

Endpoint readiness

Search condition modules available in VAPORCONE

Patient and study review

Endpoint review

Evidence package

Have a specific cohort question?